| AAV vector-mediated gene delivery to substantia nigra dopamine neurons: implications for gene therapy and disease models K Albert, MH Voutilainen, A Domanskyi, M Airavaara Genes 8 (2), 63, 2017 | 72 | 2017 |
| Characterization of a new low‐dose 6‐hydroxydopamine model of Parkinson's disease in rat AM Penttinen, I Suleymanova, K Albert, J Anttila, MH Voutilainen, ... Journal of neuroscience research 94 (4), 318-328, 2016 | 63 | 2016 |
| Back and to the future: from neurotoxin‐induced to human Parkinson's disease models M Airavaara, I Parkkinen, J Konovalova, K Albert, P Chmielarz, ... Current Protocols in Neuroscience 91 (1), e88, 2020 | 50 | 2020 |
| GDNF/RET signaling pathway activation eliminates Lewy body pathology in midbrain dopamine neurons P Chmielarz, Ş Er, J Konovalova, L Bandres, I Hlushchuk, K Albert, ... Movement Disorders 35 (12), 2279-2289, 2020 | 44 | 2020 |
| Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson’s disease K Albert, MH Voutilainen, A Domanskyi, TP Piepponen, S Ahola, ... Journal of neuroscience research 97 (3), 346-361, 2019 | 43 | 2019 |
| Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo K Albert, DP Raymundo, A Panhelainen, A Eesmaa, L Shvachiy, ... Molecular Therapy 29 (9), 2821-2840, 2021 | 32 | 2021 |
| Post-stroke intranasal (+)-naloxone delivery reduces microglial activation and improves behavioral recovery from ischemic injury JE Anttila, K Albert, ES Wires, K Mätlik, LC Loram, LR Watkins, KC Rice, ... Eneuro 5 (2), 2018 | 31 | 2018 |
| Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson’s disease in young and adult mouse MH Savolainen, K Albert, M Airavaara, TT Myöhänen Experimental Brain Research, 1-14, 2017 | 31 | 2017 |
| Neuroprotective and reparative effects of endoplasmic reticulum luminal proteins–mesencephalic astrocytederived neurotrophic factor and cerebral dopamine neurotrophic factor K Albert, M Airavaara Croatian medical journal 60 (2), 99-108, 2019 | 21 | 2019 |
| Utilising induced pluripotent stem cells in neurodegenerative disease research: focus on glia K Albert, J Niskanen, S Kälvälä, Š Lehtonen International Journal of Molecular Sciences 22 (9), 4334, 2021 | 17 | 2021 |
| Comparison of the MK-801-induced appetitive extinction deficit with pressing for reward and associated pERK1/2 staining in prefrontal cortex and nucleus accumbens MR Holahan, EP Westby, K Albert Behavioural brain research 228 (1), 194-202, 2012 | 14 | 2012 |
| Cerebral dopamine neurotrophic factor diffuses around the brainstem and does not undergo anterograde transport after injection to the substantia Nigra K Albert, JM Renko, K Mätlik, M Airavaara, MH Voutilainen Frontiers in Neuroscience 13, 453317, 2019 | 7 | 2019 |
| Cellular Models of Alpha-Synuclein Aggregation: What Have We Learned and Implications for Future Study K Albert, S Kälvälä, V Hakosalo, V Syvänen, P Krupa, J Niskanen, ... Biomedicines 10 (10), 2649, 2022 | 5 | 2022 |
| Post-stroke intranasal (+)-naloxone delivery reduces microglial activation and improves behavioral recovery from ischemic injury. eNeuro. 2018; 5 (2) JE Anttila, K Albert, ES Wires, K Matlik, LC Loram, LR Watkins, KC Rice, ... Epub 2018/05/17. doi: 10.1523/ENEURO. 0395-17.2018.[Europe PMC free article …, 0 | 2 | |
| Uptake of alpha-synuclein preformed fibrils is suppressed by inflammation and induces an aberrant phenotype in human microglia J Niskanen, S Peltonen, S Ohtonen, KC Luk, J Koistinaho, T Malm, ... | | 2024 |
